Clinical trial application for Sansheng Pharmaceutical Nafuramorphine Hydrochlorite (TRK-820) approved
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, SanshengPharmaceutical(http://(01530HK) announced that its clinicaltrial(http:// for clinicaltrials of thedrug(http:// for the treatment of itching in hemodialysis patientsthe oral dissomiasis tablets of nafurana morphine hydrochloric acid (TRK-820) was approved by the NationalMedicines(http://Regulatory Authority on September 16, 2019About TRK-820
TRK-820 is an exclusive licensed product (http:// of Sansheng Pharmaceuticals and Japan's Toray Industries, Inc In January 2018, Toray Industries, Inc granted Sansheng Pharmaceuticals exclusive rights to develop and commercialize the formulation of several oral disintegrating tablet formulations of TRK-820 in the mainland of the People's Republic of China (excluding Hong Kong, Macau and Taiwan) TRK-820 is a highly selective (kappa)-opioid receptor agonist developed by Toray TRK-820's softcapsule form has been available in Japan since 2009 to treat hemodialysis-related uremia itching Other indications of TRK-820, including itching in patients with chronic liver disease and itching in patients with peritoneal dialysis, were approved in Japan in 2015 and 2017, respectively
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
